In August 2005, Bioren was acquired by Pfizer. Bioren is a developer of tools to design, discover, and optimize human antibodies for drugs. The Company uses a unique set of proprietary tools to design, discover and optimize human antibodies for existing drugs and for Biorenâs proprietary products. Biorenâs platform technology dramatically reduces the time and cost associated with discovery, maximizes the performance of molecules prior to entering clinical development, provides a strong and unique Intellectual Property for the protection of clinical/commercial candidates and avoids the royalties âstackingâ typically associated with the industry. Bioren has developed Walk-Through Mutagenesis (WTMTM) and Look-Through Mutagenesis (LTMTM) technologies to improve the drug development of anti
